Literature DB >> 16167064

Intraperitoneal linear polyethylenimine (L-PEI)-mediated gene delivery to ovarian carcinoma nodes in mice.

M-H Louis1, S Dutoit, Y Denoux, P Erbacher, E Deslandes, J-P Behr, P Gauduchon, L Poulain.   

Abstract

Linear polyethylenimine (L-PEI) is an efficient transfection agent for ovarian carcinoma cells in vitro and ex vivo. In the present work, we go a step further and evaluate the efficacy of L-PEI in human ovarian tumor nodes developed in mice. PEI/DNA complexes were administered intraperitoneally instead of intravenously to avoid sequestering of complexes in the lung and liver and to allow transfection of nonvascularized tumor nodes. Plasmid biodistribution was studied by PCR and gene expression was characterized using complementary luciferase and beta-galactosidase assays. Intraperitoneal (i.p.) injection of L-PEI/DNA complexes allowed the straightforward distribution of plasmid in the whole peritoneal cavity. Gene expression occurred in many organs, but tumor nodes appeared as preferential sites for transgene expression. The i.p. delivery route allowed repeated injections and administration of large amounts of DNA (up to 400 mug) without signs of toxicity, even for doses well beyond the intravenous lethal dose. Transgene expression was dose-dependent and transient. However, multiple injections allowed its persistence to increase. These results provide encouraging elements towards the development of PEI-based gene therapy protocols for the treatment of advanced stage ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16167064     DOI: 10.1038/sj.cgt.7700893

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  13 in total

1.  Targeting diphtheria toxin and TNF alpha expression in ovarian tumors using the H19 regulatory sequences.

Authors:  Aya Mizrahi; Abraham Hochberg; Smadar Amiur; Jennifer Gallula; Imad Matouk; Tatiana Birman; Tally Levy; Sorin Ladimir; Patricia Ohana
Journal:  Int J Clin Exp Med       Date:  2010-09-21

2.  Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles.

Authors:  D H Park; B K Jung; Y S Lee; J Y Jang; M K Kim; J K Lee; H Park; J Seo; C W Kim
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

Review 3.  Gene therapy for ovarian cancer.

Authors:  Kristopher J Kimball; T Michael Numnum; Rodney P Rocconi; Ronald D Alvarez
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

4.  Linear Polyethylenimine-DNA Nanoconstruct for Corneal Gene Delivery.

Authors:  Jason T Rodier; Ratnakar Tripathi; Michael K Fink; Ajay Sharma; Madhuri Korampally; Shubhra Gangopadhyay; Elizabeth A Giuliano; Prashant R Sinha; Rajiv R Mohan
Journal:  J Ocul Pharmacol Ther       Date:  2019 Jan/Feb       Impact factor: 2.671

5.  Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Authors:  Juan R Cubillos-Ruiz; Xavier Engle; Uciane K Scarlett; Diana Martinez; Amorette Barber; Raul Elgueta; Li Wang; Yolanda Nesbeth; Yvon Durant; Andrew T Gewirtz; Charles L Sentman; Ross Kedl; Jose R Conejo-Garcia
Journal:  J Clin Invest       Date:  2009-07-13       Impact factor: 14.808

6.  Fatty acid-based strategy for efficient brain targeted gene delivery.

Authors:  Jie Shen; Mei Yu; Qinggang Meng; Jin Li; Yifan Lv; Weiyue Lu
Journal:  Pharm Res       Date:  2013-04-23       Impact factor: 4.200

7.  Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo.

Authors:  Janjira Intra; Aliasger K Salem
Journal:  J Control Release       Date:  2008-04-24       Impact factor: 9.776

8.  Transgene therapy for rat anti-Thy1.1 glomerulonephritis via mesangial cell vector with a polyethylenimine/decorin nanocomplex.

Authors:  Jian-Yong Sun; Yu Sun; Hui-Juan Wu; Hong-Xia Zhang; Zhong-Hua Zhao; Qi Chen; Zhi-Gang Zhang
Journal:  Nanoscale Res Lett       Date:  2012-08-09       Impact factor: 4.703

9.  Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences.

Authors:  Aya Mizrahi; Abraham Czerniak; Tally Levy; Smadar Amiur; Jennifer Gallula; Imad Matouk; Rasha Abu-lail; Vladimir Sorin; Tatiana Birman; Nathan de Groot; Abraham Hochberg; Patricia Ohana
Journal:  J Transl Med       Date:  2009-08-06       Impact factor: 5.531

10.  Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer.

Authors:  Ajay Sharma; Jason T Rodier; Ashish Tandon; Alexander M Klibanov; Rajiv R Mohan
Journal:  Mol Vis       Date:  2012-10-20       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.